AstraZeneca

10 pharmas form nonprofit TransCelerate to accelerate R&D of new medicines

Wednesday, September 19, 2012 02:46 PM

Ten biopharmaceutical companies have formed a non-profit organization, TransCelerate BioPharma, to accelerate the development of new medicines. Participants include Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech and Sanofi.

More... »

AstraZeneca, Broad Institute partner on discovery of antibacterial and antiviral agents

Wednesday, September 12, 2012 09:09 AM

AstraZeneca and the Broad Institute in Cambridge, Mass., have formed a collaboration to identify new chemical compounds targeting bacterial and viral infections that could speed the development of new antibacterial and antiviral drugs.

More... »

MedImmune, WuXi AppTec form joint venture to develop novel biologic for Chinese market

Monday, September 10, 2012 10:31 AM

MedImmune, the global biologics arm of AstraZeneca, and WuXi AppTec, an R&D outsourcing company, have formed a joint venture to develop and commercialize MEDI5117, a novel biologic for autoimmune and inflammatory diseases, in China.

More... »

Pascal Soriot named AstraZeneca CEO

Tuesday, August 28, 2012 03:06 PM

AstraZeneca has announced Pascal Soriot’s appointment as the company’s chief executive officer. He will assume the new role and join the AstraZeneca board as an executive director as of Oct. 1.

More... »

AstraZeneca, Pfizer enter agreement for OTC Nexium

Wednesday, August 15, 2012 09:41 AM

AstraZeneca, a global biopharmaceutical company, has entered into an agreement with Pfizer, a global research-based pharmaceutical company, for the over-the-counter (OTC) rights for Nexium (esomeprazole magnesium), a prescription drug currently approved to treat the symptoms of gastroesophageal reflux disease (GERD).

More... »

MedImmune to close vaccines sites in California

Tuesday, July 17, 2012 02:55 PM

Gaithersburg, Md.-based MedImmune, the global biologics arm of AstraZeneca, is restructuring its infectious disease and vaccines research, development and operations, closing its Mountain View, Calif., and Santa Clara, Calif., sites and consolidating its infectious disease and vaccines R&D to other existing sites. The changes are expected to be completed in 2014.

More... »

AstraZeneca acquires neuroscience assets from Link Medicine

Friday, July 13, 2012 03:20 PM

AstraZeneca has acquired a portfolio of neuroscience assets from Link Medicine, a privately held biopharmaceutical company based in Massachusetts. Link Medicine has focused its R&D efforts in the field of autophagy, an intracellular process that clears and recycles misfolded proteins, and has been developing potential new treatments for a range of neurodegenerative diseases.

More... »

AstraZeneca in A5 alliance for Alzheimer’s

Friday, July 13, 2012 03:14 PM

AstraZeneca and Dr. Steven Paul of Weill Cornell Medical College have announced a first of its kind research alliance that brings four leading academic research laboratories together with AstraZeneca to study a major risk factor for Alzheimer's disease, the apolipoprotein E4 genotype (ApoE).

More... »

BMS acquires Amylin Pharmaceuticals, expands diabetes alliance with AstraZeneca

Monday, July 2, 2012 09:59 AM

Global biopharmaceutical company Bristol-Myers Squibb (BMS) has agreed to acquire Amylin Pharmaceuticals of San Diego for $31.00 per share in cash, pursuant to a cash tender offer and second step merger, or an aggregate purchase price of approximately $5.3 billion.

More... »

AstraZeneca, Karolinska Institutet collaborate on molecular imaging research

Thursday, June 21, 2012 04:29 PM

Global biopharmaceutical company AstraZeneca and Karolinska Institutet, a medical university in Sweden, have entered into a three year collaborative research agreement that will apply state-of-the-art molecular imaging technologies to generate novel diagnostic imaging tools and further the development of AstraZeneca’s neuroscience R&D pipeline.

More... »